Year: 2024

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China, Australia, and IndiaBoston (October 22, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today announced that the European Patent Office (EPO) has issued a formal notice of its intention to grant a patent for Allarity’s Drug Response Predictor (DRP®) companion diagnostic specific to stenoparib, the Company’s dual-targeted PARP/Tankyrase inhibitor. This patent represents a significant step forward in securing Allarity’s market position for stenoparib...

Yara International ASA third quarter 2024 results will be published on Friday, 25 October 2024 at 08:00 CEST. You can follow the third-quarter results presentation online at 12:00 CEST. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at https://yara.com/investor-relations/latest-quarterly-report/ There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management. Please use the link to register for this session: https://registrations.events/direct/Q4I418631 Registered conference call participants will receive a confirmation with a full list of available international dial-in numbers and a unique passcode. If you do not see the email in a few minutes after completed registration, please check the “junk mail”...

MILWAUKEE, Oct. 22, 2024 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN), today announced that it will release its fiscal 2025 first-quarter results at approximately 8:00 am Eastern on November 6, 2024, and host a webcast and conference call to discuss those results at 9:00 am Eastern. Following their prepared remarks, the Company will host a question-and-answer session with the investment community. The live audio webcast will be available on Twin Disc’s website at https://ir.twindisc.com. To participate in the conference call, please dial (646) 968-2525 approximately ten minutes before the call is scheduled to begin. A replay of the webcast will be available at https://ir.twindisc.com shortly after the call until November 5, 2025. About Twin DiscTwin Disc, Inc. designs, manufactures and sells marine and heavy-duty off-highway...

OREM, Utah, Oct. 22, 2024 (GLOBE NEWSWIRE) — Reflect Scientific Inc. (OTCQB: RSCF), a leading innovator in cryogenic technology, announced today that it has received a $225,000 order for its state-of-the-art blast freezing systems from an existing customer, a prominent Asia-based BioPharma company. This order marks the eighth follow-on order from this client, demonstrating their full adoption and standardization of Reflect Scientific’s advanced freezing technology. The continued partnership underscores the Company’s strong position in the global biotech market and the reliability of its products. “This repeat order validates the superior performance and cost-effectiveness of our freezer systems,” said Kim Boyce, CEO of Reflect Scientific. “Our technology continues to meet the demanding requirements...

Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions IT and ICM administration achieved comparable biodistribution across brain and spinal cord regions in NHPs Findings from the analysis reaffirm the clinical potential of IT administration as an effective, safe and minimally invasive approach to deliver AAV-based gene therapies designed to treat CNS diseases in both children and adults DALLAS, Oct. 22, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will...

WALNUT, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) — Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, today announced enhancements to its Warehouse Management System (WMS) through the integration of artificial intelligence (AI). The upgraded WMS  system is set to transform the way Armlogi streamlines operations, optimizes inventory management, and enhances overall efficiency across its global warehousing operations. Armlogi’s upgraded WMS is designed to reduce new users’ learning curve, minimize operational errors, and enhance productivity. By integrating AI, the system is expected to predict future inventory requirements and optimize warehouse layouts...

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) — Cayson Acquisition Corp (NASDAQ:CAPNU) (the “Company”) announced today that, commencing on or about October 24, 2024, holders of its units sold in the Company’s initial public offering may elect to separately trade the Company’s ordinary shares and rights included in the units. The ordinary shares and rights that are separated will trade on the Nasdaq Global Market (“Nasdaq”) under the symbols “CAPN” and “CAPNR,” respectively. No fractional rights will be issued upon separation of the units and only whole rights will trade. Those units not separated will continue to trade on Nasdaq under the symbol “CAPNU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into ordinary...

WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the clinical and preclinical development of its novel first-in-class lead radiopharma program based on MNPR-101 at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress held in Hamburg, Germany. MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. The slides for Monopar’s oral presentation can be found at the following link: https://www.monopartx.com/pipeline/mnpr-101/eanm24-ppt. Monopar’s presentation, accepted as a “Top-Rated Oral Presentation” within the Scientific Program, illustrates...